Press Releases

Approval Helps Solidify NexoBrid’s Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages YAVNE, Israel, Aug. 15, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced

Completed Construction of New NexoBrid ® Manufacturing Facility €16.25 Million EIC Funding Expedites EscharEx ® Development for Diabetic Foot Ulcer s , Significantly Expanding the Addressable Market ; Phase III Study for Venous Leg Ulcers to Begin in H2 2024 $25 Million Strategic Investment Led by

NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients YAVNE, Israel, Aug. 05, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today

Conference Call and Webcast Scheduled for Wednesday, August 14th at 8:30 am Eastern Time YAVNE, Israel, Aug. 02, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its

Research Published in THE LANCET's eClinicalMedicine EscharEx ® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue YAVNE, Israel, July 29, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic

Funds to be used for clinical development of EscharEx ® to treat diabetic foot ulcers (DFUs) Award advances MediWound’s DFU program and its future revenues four years ahead of original schedule YAVNE, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd.

Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investment YAVNE, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the world leader in next-generation enzymatic therapeutics for tissue repair, today announced it

 NexoBrid ® interest surges; $5 million in Q1 2024 revenue, with $24 million forecast for the year Manufacturing facility on target for completion by mid-2024 EscharEx ® Phase III study to launch 2H 2024 Company set to join Russell 3000® Index Conference call today, May 29 at 8:30am Eastern Time

Conference Call and Webcast Scheduled for Wednesday, May 29th at 8:30 am Eastern Time YAVNE, Israel, May 22, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its

Oral presentations include additional comparative data between EscharEx ® and SANTYL ® , and new analyses show strong correlation between wound bed preparation and wound healing Analyses validate the planned design and endpoints of the upcoming Phase III study YAVNE, Israel, April 25, 2024 (GLOBE